IP Library Granted Patent US 7,332,507
Granted Patent B2
US 7,332,507 · App. 10/512,570 · Granted Feb 19, 2008

3-substituted quinuclidines and their use

Assignee: Neurosearch A/S
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,332,507
App. No.
10/512,570
Granted
Feb 19, 2008
Kind
B2
Abstract

This invention relates to novel 3-substituted quinuclidine derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

Claims (12)

1. A 3-substituted quinuclidine derivative, represented by Formula V:

or by Formula VII:

any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, or an aza-onium-salt thereof, wherein R 1 and R 2 , independently of each other, represent hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, alkoxyalkyl, hydroxyalkoxy, halo, haloalkyl, hydroxy, haloalkoxy, cyano, amino, nitro or phenyl.

2. The quinuclidine derivative of claim 1 , wherein R 1 and R 2 , independently of each other, represent hydrogen, alkyl, alkoxy, halo, haloalkyl, hydroxy, cyano, amino, nitro or phenyl.

3. The quinuclidine derivative of claim 1 , wherein one of R 1 and R 2 represents hydrogen, and the other of R 1 and R 2 represents alkyl, alkoxy, halo, haloalkyl, hydroxy, cyano, amino, nitro or phenyl.

4. The quinuclidine derivative of claim 1 , which is

(±)-3-(1-Benzimidazolyl)-quinuclidine;

(±)-3-(2-Trifluoromethyl-1-benzimidazolyl)-quinuclidine;

(±)-3-(5-Trifluoromethyl-1-benzimidazolyl)-quinuclidine; or

(±)-3-(1-Benzotriazolyl)-guinuclidine;

any of its enantiomers or any mixture of enantiomers, or a pharmaceutically acceptable salt thereof, or an aza-onmum-salt thereof.

5. A pharmaceutical composition comprising a 3-substituted quinuclidine derivative of claim 1 , any of its enantiomers or any mixture of enantiomers, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier or diluent.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2013
From: NEUROSEARCH A/S
To: ANIONA APS
Reel/Frame 030049/0894 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 26, 2004
From: PETERS, DAN; OLSEN, GUNNAR M.; NIELSEN, ELSEBET O.; AHRING, PHILIP K.; JORGENSEN, TINO D.
To: NEUROSEARCH A/S
Reel/Frame 016667/0028 →
Priority Claims (1)
DK 2002 00834 · May 30, 2002 · national
Continuity (1)
Related Publication 20050176756A1 · Aug 11, 2005